RT Journal Article
SR Electronic
T1 Safety of 6000 intravitreal dexamethasone implants
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 39
OP 46
DO 10.1136/bjophthalmol-2019-313991
VO 104
IS 1
A1 Bindu Rajesh
A1 Javier Zarranz-Ventura
A1 Adrian T Fung
A1 Catharina Busch
A1 Niroj Kumar Sahoo
A1 Patricio J Rodriguez-Valdes
A1 Valentina Sarao
A1 Sanjay Kumar Mishra
A1 A Osman Saatci
A1 Patricia Udaondo Mirete
A1 Giuseppe Querques
A1 Michel Eid Farah
A1 Paolo Lanzetta
A1 J Fernando Arevalo
A1 Laurent Kodjikian
A1 Jay Chhablani
A1 ,
YR 2020
UL http://bjo.bmj.com/content/104/1/39.abstract
AB Purpose To evaluate the real-life safety profile of intravitreal dexamethasone implant injection for various retinal conditions.Methods Retrospective multicenter analysis of intravitreal dexamethasone implant injections (700 µg) due to various retinal conditions including central retinal venous occlusion (1861 injections), diabetic macular oedema (3104 injections), post-surgical cystoid macular oedema (305 injections) and uveitis (381 injections). The eyes were evaluated mainly for the occurrence of adverse events such as glaucoma, cataract, retinal detachment and endophthalmitis along during the follow-up period.Results A total of 6015 injections in 2736 eyes of 1441 patients (mean age of 65.7±12.9 years) were in total analysed over an average period of 18 months (range 6 months to 102 months). A total of 576 eyes (32.5% of the phakic eyes) developed cataract requiring surgical intervention. However, visually insignificant cataract progression was observed in another 259 phakic eyes (14.6%) which did not require surgical removal. A total of 727 eyes (26.5%) experienced an intraocular pressure (IOP) rise of >25 mm Hg, with 155 eyes (5.67%) having a prior history of glaucoma and 572 eyes (20.9%) having new onset IOP rise. Overall, more than 90% of eyes with IOP rise were managed medically, and 0.5% eyes required filtering surgery. Endophthalmitis (0.07%), retinal detachment (0.03%) and vitreous haemorrhage (0.03%) were rare. There was no significant change in visual acuity (p=0.87) and central macular thickness (p=0.12) at the last follow-up.Conclusion This is the largest real-life study assessing the safety of intravitreal dexamethasone implant injections in various retinal conditions. Cataract progression and intraocular pressure rise are the most common side effects, but are often rather easily manageable.